Delivery Order 36F79721D0166-36C26026F0294

Biocryst Pharmaceuticals Inc. was awarded a delivery order valued at $242,987 by Veterans Integrated Service Network (VISN) 20 on March 12, 2025, for the supply of bulk Orladeyo pharmaceutical with a 2025 price increase adjustment. The contract utilizes a firm fixed price structure under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and represents an open market award with no set-aside designation. Performance will be completed by March 11, 2026, with the work performed in...

This is a delivery order contract awarded to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. The contract is valued at $201,721.59 and has an ultimate completion date of October 4, 2024. The contract is for the delivery of ORLADEYO 150MG CAPS, a pharmaceutical product used to treat hereditary angioedema. The contract was awarded by the U.S. Department of Veterans Affairs (VA), specifically the Veterans Integrated...

This is a $382,300.88 firm fixed-price delivery order contract awarded by the Veterans Integrated Service Network 20 (VISN 20) of the U.S. Department of Veterans Affairs (VA) to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing drugs for rare diseases. The contract is for the bulk order of ORLADEYO, a drug used to treat hereditary angioedema, to support veteran healthcare. The contract is not set aside and is part of Biocryst's Federal Supply Schedule (FSS)...

This federal contract award was made by the Veterans Integrated Service Network 20 (VISN 20), a civilian agency, to Biocryst Pharmaceuticals Inc., a biotechnology company specializing in rare disease pharmaceuticals. The $379,939.32 firm fixed-price delivery order contract is for the supply of BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO), a medication used to treat hereditary angioedema. The contract has an ultimate completion date of September 30, 2025 and was awarded on October 1, 2024. The...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded a $113,440.80 delivery order to Biocryst Pharmaceuticals, Inc. under the firm fixed price Pharmaceuticals and Drugs Federal Supply Schedule contract. This order is for the delivery of BEROTRALSTAT HCL 150MG CAP,ORAL BULK to the place of performance in Durham, North Carolina by May 31, 2023. The contract was awarded on June 1, 2022 and has no set-aside designation. Biocryst...

This federal contract award is for ORLADEYO EMERGENT, a pharmaceutical product, to Biocryst Pharmaceuticals Inc. as the prime contractor. The contract has a ceiling value of $29,649.88 and is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract (36F79721D0166) for Pharmaceuticals and Drugs with the Department of Veterans Affairs (VA). Biocryst is a biotechnology company that specializes in the development of small molecule drugs for rare diseases, and it primarily supplies...

Biocryst Pharmaceuticals, Inc. was awarded a $56,670.76 firm fixed price delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20. The contract calls for the delivery of berotralstat to Roseburg, Oregon with a period of performance concluding on January 19, 2024. No set-aside designation was applied to this award issued against GSA Schedule 61-IB for pharmaceutical...

<p>The Defense Logistics Agency issued a delivery order to Amerisourcebergen Drug Corp on February 5, 2026, for ORGOVYX 120 mg tablets, with a ceiling value of $4,380.39. The order is issued under a parent Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 2026.</p> <p>Place of performance is Conshohocken, PA. Ultimate completion date is February 27, 2026. The order carries firm fixed pricing and no set-aside.</p>

<p>The Defense Logistics Agency issued a $1,460.13 delivery order to AmerisourceBergen Drug Corp on February 2, 2026, for ORGOVYX 120 mg tablets (30-count unit of use packaging). The order is a call against the company's existing Indefinite Delivery Contract with DLA Troop Support Medical.</p> <p>Place of performance is Conshohocken, PA. Ultimate completion date is February 24, 2026. Pricing is firm fixed price. No set-aside was used.</p>

The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of ORGOVYX 120 MG tablets (30-count units) valued at $2,920.26. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded procurement. The order is scheduled for completion by January 2, 2026, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents one...